Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Med Oncol ; 32(12): 259, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26519258

ABSTRACT

Targeted therapy focused on highly expressed growth factor receptors is increasingly becoming popular for the treatment of lung cancer. Cancer cells exhibit higher levels of macropinocytosis than the normally quiescent non-cancerous cells, which can further be enhanced by growth factors. Here, we show the targeted enhancement of macropinocytosis in lung cancer cells for the delivery of the mitochondriotoxic peptide (KLAKLAK)2 using keratinocyte growth factor (KGF). We report the formation of a nanoparticle (NP) comprising of two chimeric fusion proteins, both fused to elastin-like polypeptide (ELP), (KLAKLAK)2-ELP and KGF-ELP. We show that (KLAKLAK)2-ELP nanoparticles are internalized via macropinocytosis and its internalization is facilitated by the interaction of the ELP domain with cell surface heparin sulfate proteoglycans. This internalization leads to mitochondrial depolarization and subsequent cell death. Also, we demonstrate that KGF-ELP selectively enhances macropinocytosis in cancer cells expressing high levels of the keratinocyte growth factor receptor (KGFR). Finally, the heterogeneous NPs consisting of (KLAKLAK)2-ELP and KGF-ELP selectively kill KGFR-expressing lung cancer cells. Hence, this multipronged approach of targeting highly active processes and receptors in cancer cells will be tremendously selective in the treatment of both early-stage and advanced-stage lung cancers, thereby improving patient's prognosis and survival rate.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Drug Delivery Systems/methods , Lung Neoplasms/metabolism , Pinocytosis/drug effects , Receptor, Fibroblast Growth Factor, Type 2/pharmacology , Recombinant Fusion Proteins/pharmacokinetics , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Elastin , Humans , Receptor, Fibroblast Growth Factor, Type 2/chemistry , Receptor, Fibroblast Growth Factor, Type 2/pharmacokinetics , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/pharmacology
2.
Biol Pharm Bull ; 35(5): 731-6, 2012.
Article in English | MEDLINE | ID: mdl-22687409

ABSTRACT

We have developed a strong inhibitor (S252W mutant soluble ectodomain of fibroblast growth factor recptor-2 IIIc, msFGFR2) that binds FGFs strongly and blocks the activation of FGFRs. In vitro, msFGFR2 could inhibit the promoting effect of transforming growth factor (TGF)-ß1 on the proliferation of primary lung fibroblasts. In vivo, msFGFR2 alleviated lung fibrosis through inhibiting the expression of α-smooth muscle actin (SMA) and collagen deposit. In Western blotting of the right lung tissues and immunohistochemical assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-ß signals were blocked meanwhile. In summary, msFGFR2 attenuated BLM-induced fibrosis and is an attractive therapeutic candidate for human pulmonary fibrosis.


Subject(s)
Fibroblast Growth Factors/metabolism , Fibroblasts/drug effects , Lung/drug effects , Peptide Fragments/therapeutic use , Pulmonary Fibrosis/prevention & control , Receptor, Fibroblast Growth Factor, Type 2/therapeutic use , Receptors, Fibroblast Growth Factor/metabolism , Recombinant Proteins/therapeutic use , Transforming Growth Factor beta1/metabolism , Actins/metabolism , Animals , Bleomycin , Blotting, Western , Cell Proliferation/drug effects , Collagen/metabolism , Fibroblasts/cytology , Fibroblasts/metabolism , Lung/pathology , Male , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinases/metabolism , Peptide Fragments/pharmacology , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/metabolism , Receptor, Fibroblast Growth Factor, Type 2/pharmacology , Recombinant Proteins/pharmacology , Smad3 Protein/metabolism
3.
Mol Cancer Ther ; 10(9): 1656-66, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21750221

ABSTRACT

The fibroblast growth factor (FGF) signaling pathway is a recognized target of cancer therapy. We have developed a strong inhibitor (S252W mutant soluble ectodomain of FGF recptor-2 IIIc, msFGFR2) that binds FGFs and blocks the activation of FGFRs. Thermodynamic binding studies indicated that msFGFR2 bound FGF-2 16.9 times as strongly as wild-type soluble FGFR2IIIc ectodomain (wsFGFR2). It successfully suppressed the growth, angiogenesis, and metastasis of two tumor cell lines in vitro and in vivo, and it potently inhibited cancer cell proliferation but not normal cell proliferation. Therefore, msFGFR2 is a useful probe for FGF-dependent signaling pathways and a potential broad-spectrum antitumor agent.


Subject(s)
Antineoplastic Agents/pharmacology , Peptide Fragments/pharmacology , Receptor, Fibroblast Growth Factor, Type 2/genetics , Receptor, Fibroblast Growth Factor, Type 2/pharmacology , Recombinant Proteins/pharmacology , Animals , Apoptosis/drug effects , Cell Line, Transformed , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Humans , Kaplan-Meier Estimate , Ligands , Mice , Mice, Inbred BALB C , Mice, Nude , Mutant Proteins/genetics , Mutant Proteins/pharmacology , Mutant Proteins/therapeutic use , NIH 3T3 Cells , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/pathology , Neoplasms/drug therapy , Neoplasms/mortality , Neoplasms/pathology , Neovascularization, Physiologic/drug effects , Peptide Fragments/chemistry , Peptide Fragments/therapeutic use , Protein Binding , Receptor, Fibroblast Growth Factor, Type 2/chemistry , Receptor, Fibroblast Growth Factor, Type 2/therapeutic use , Recombinant Proteins/chemistry , Recombinant Proteins/therapeutic use , Signal Transduction/drug effects , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
4.
Acta Cir Bras ; 25(1): 93-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20126895

ABSTRACT

PURPOSE: To evaluate effects of oxidative stress and supplementation of keratinocyte growth factor (KGF) on cultivated human keratinocytes. METHODS: Oxidative stress was produced through addition of hydrogen peroxide (H(2)O(2)) to the culture medium. Cultivated human keratinocytes were divided in 4 groups: Group control (G C), Group KGF (G KGF), Group H(2)O(2) (G H(2)O(2)), Group H(2)O(2) and KGF (G H(2)O(2)-KGF). Each experiment was accomplished with the same lineage cultivated keratinocytes, in triplicate. Cell viability was evaluated by trypan blue exclusion assay. RESULTS: The results showed that the culture medium supplemented with KGF presented a small rate of cell viability when compared to cells only in culture medium (p<0,001). It demonstrated that only the growth factor does not have protector effects for cells in vitro. However, in front of the oxidative stress produced by addition of hydrogen peroxide to the medium, KGF showed a beneficial effect, protecting cells when compared to the group that suffered hydrogen peroxide action but had not been exposed to KGF (p<0,001). CONCLUSION: KGF determined protection to the primary human keratinocytes exposed to oxidative stress.


Subject(s)
Antioxidants/pharmacology , Keratinocytes/drug effects , Oxidative Stress/drug effects , Receptor, Fibroblast Growth Factor, Type 2/pharmacology , Cells, Cultured , Humans , Hydrogen Peroxide/administration & dosage , Keratinocytes/cytology
5.
Physiol Genomics ; 27(3): 380-90, 2006 Nov 27.
Article in English | MEDLINE | ID: mdl-16940428

ABSTRACT

Synectin (GIPC1), a receptor scaffold protein, has been isolated by our laboratory as a syndecan-4 cytoplasmic domain binding partner that regulates important aspects of cell motility (Gao Y, Li M, Chen W, Simons M. J Cell Physiol 184: 373-379, 2000; Tkachenko E, Elfenbein A, Tirziu D, Simons M. Circ Res 98: 1398-1404, 2006). Moreover, synectin plays a major role in arterial morphogenesis and in growth factor signaling in arterial endothelial cells by regulating Rac1 activity (Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein A, Ruiz de Almodovar C, Dedkov E, Tomanek R, Li W, Westmore M, Singh J, Horowitz A, Mulligan-Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M. Dev Cell 10: 783-795, 2006). The present study was carried out to characterize changes in synectin-dependent gene expression induced by homozygous disruption of the gene in endothelial cells. Using a combination of suppression subtraction hybridization and high throughput microarray technology, we have identified aberrant biological processes of transcriptional regulation in synectin(-/-) primary endothelial cells including abnormal basal regulation of genes associated with development, cell organization and biogenesis, intracellular tracking, and cell adhesion. Analysis of gene expression following FGF2 treatment demonstrated significant abnormalities in transcription, cytoskeletal organization and biogenesis, and protein modification and transport in synectin(-/-) compared with synectin(+/+) endothelial cells. These results confirm synectin involvement in FGF2-dependent signal transduction and provide insights into synectin-dependent gene expression in the endothelium.


Subject(s)
Carrier Proteins/genetics , Carrier Proteins/physiology , Endothelial Cells/physiology , Gene Expression Regulation , Neuropeptides/genetics , Neuropeptides/physiology , Adaptor Proteins, Signal Transducing , Animals , Cell Adhesion , Cell Separation , Endothelial Cells/cytology , Gene Expression Regulation/drug effects , Heart , Lung/cytology , Mice , Mice, Knockout , Nucleic Acid Hybridization/methods , Oligonucleotide Array Sequence Analysis , Receptor, Fibroblast Growth Factor, Type 2/pharmacology
6.
Stem Cells ; 24(3): 748-62, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16166253

ABSTRACT

Neurospheres (NSs) are clonal cellular aggregates composed of neural stem cells and progenitors. A comprehensive description of their proliferation and differentiation regulation is an essential prerequisite for their use in biotherapies. Cytokines are essential molecules regulating cell precursor fate. Using a gene-array strategy, we conducted a descriptive and functional analysis of endogenous cytokines and receptors expressed by spinal cord-derived NSs during their growth or their differentiation into neuronal and glial cells. NSs were found to express approximately 100 receptor subunits and cytokine/secreted developmental factors. Several angiogenic factors and receptors that could mediate neural precursor cell-endothelial cell relationships were detected. Among them, receptor B for endothelins was highly expressed, and endothelins were found to increase NS growth. In contrast, NSs express receptors for ciliary neurotrophic factor (CNTF), bone morphogenetic protein (BMP), interferon (IFN)-gamma, or tumor necrosis factor (TNF)-alpha, which, when added in the growth phase, led to a dramatic growth reduction followed by a reduction or a loss of oligodendrocyte formation on differentiation. In addition, NSs synthesize fibroblast growth factor 2/epidermal growth factor (FGF2/EGF)-regulated endogenous cytokines that participate in their growth and differentiation. Notably, BMP-7 and CNTF were expressed during expansion, but upon differentiation there was a remarkable switch from BMP-7 to BMP-4 and -6 and a sharp increase of CNTF. Reintroduction of growth factors reverses the BMP expression profile, indicating growth factor-BMP cross-regulations. The role of endogenous CNTF was investigated by deriving NSs from CNTF knockout mice. These NSs have an increased growth rate associated with reduction of apoptosis and generate astrocytes with a reduced glial fibulary acidic protein (GFAP) content. These results demonstrate the combined role of endogenous and exogenous cytokines in neural precursor cell growth and differentiation.


Subject(s)
Cell Proliferation , Epidermal Growth Factor/metabolism , Ganglia, Spinal/physiology , Receptor, Fibroblast Growth Factor, Type 2/metabolism , Stem Cells/physiology , Animals , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Epidermal Growth Factor/pharmacology , Ganglia, Spinal/cytology , Mice , Mice, Transgenic , Neurons/cytology , Neurons/physiology , Oligodendroglia/cytology , Oligodendroglia/physiology , Receptor, Fibroblast Growth Factor, Type 2/pharmacology , Stem Cells/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...